Evidence map›Paper›PMID 34563208›Full record

Observational studyHealth and quality of life outcomes2021

Health-related quality of life in men with localized prostate cancer treated with radiotherapy: validation of an abbreviated version of the Expanded Prostate Cancer Index Composite for Clinical Practice in Spain.

Almudena Zapatero, Xavier Maldonado Pijoan, Antonio Gómez-Caamaño, José Pardo Masferrer, Víctor Macías Hernández, Asunción Hervás Morón, Julia Luisa Muñoz García, Amalia Palacios Eito, Paloma Anguita-Alonso, Cristina González-Junco and 1 more

Abstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Health and quality of life outcomes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Almudena ZapateroDepartment of Radiation Oncology, Hospital Universitario de La Princesa, Madrid, Spain. almudena.zapatero@salud.madrid.org.ORCID http://orcid.org/0000-0003-2930-2312
Xavier Maldonado PijoanDepartment of Radiation Oncology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Antonio Gómez-CaamañoDepartment of Radiation Oncology, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain.
José Pardo MasferrerDepartment of Radiation Oncology, Hospital Universitari Son Espases, Palma de Mallorca, Spain.
Víctor Macías HernándezHospital Universitario Y Politecnico La Fe, Valencia, Spain.
Asunción Hervás MorónDepartment of Radiation Oncology, Hospital Ramon Y Cajal, Madrid, Spain.
Julia Luisa Muñoz GarcíaDepartment of Radiation Oncology, Hospital Infanta Cristina de Badajoz, Badajoz, Spain.
Amalia Palacios EitoDepartment of Radiation Oncology, Hospital Universitario Reina Sofía, Córdoba, Spain.
Paloma Anguita-AlonsoAstellas Pharma Inc., Madrid, Spain.
Cristina González-JuncoAstellas Pharma Inc., Madrid, Spain.
José López TorrecillaDepartment of Radiation Oncology, ERESA, Hospital General Universitario de València, València, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHealth-related quality of life (HRQoL) is greatly affected by prostate cancer (PCa) and associated treatments. This study aimed to measure the impact of radiotherapy on HRQoL and to further validate the Spanish version of the 16-item Expanded Prostate Cancer Index Composite (EPIC-16) in routine clinical practice.

methodsAn observational, non-interventional, multicenter study was conducted in Spain with localized PCa patients initiating treatment with external beam radiotherapy (EBRT) or brachytherapy (BQT). Changes from baseline in EPIC-16, University of California-Los Angeles Prostate Cancer Index (UCLA-PCI), and patient-perceived health status were longitudinally assessed at end of radiotherapy (V2) and 90 days thereafter (V3). Psychometric evaluations of the Spanish EPIC-16 were conducted.

resultsOf 516 patients enrolled, 495 were included in the analysis (EBRT, n = 361; BQT, n = 134). At baseline, mean (standard deviation [SD]) EPIC-16 global scores were 11.9 (7.5) and 10.3 (7.7) for EBRT and BQT patients, respectively; scores increased, i.e., HRQoL worsened, from baseline, by mean (SD) of 6.8 (7.6) at V2 and 2.4 (7.4) at V3 for EBRT and 4.2 (7.6) and 3.9 (8.2) for BQT patients. Changes in Spanish EPIC-16 domains correlated well with urinary, bowel, and sexual UCLA-PCI domains. EPIC-16 showed good internal consistency (Cronbach's alpha = .84), reliability, and construct validity.

conclusionThe Spanish EPIC-16 questionnaire demonstrated sensitivity, strong discriminative properties and reliability, and validity for use in clinical practice. EPIC-16 scores worsened after radiotherapy in different HRQoL domains; however, a strong tendency towards recovery was seen at the 3-month follow-up visit.

Indexed as

Health Status IndicatorsQuality of LifeAgedBrachytherapyHumansMaleMiddle AgedProstatectomyProstatic NeoplasmsReproducibility of ResultsSpainSurveys and QuestionnairesBrachytherapyEPICProstate cancerQuality-of-life assessmentRadiotherapy

Identifiers

PMID34563208
PMCPMC8466718

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.